Perceptive Advisors’s Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible PPHMP Stock Holding History

Perceptive Advisors’s Portfolio PPHMP Stock Details PPHMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-200,000	Closed	-$4.34M	–	187
2017 Q1	$4.34M	Hold	200,000	–	–	0.25%	66
2016 Q4	$3.98M	Buy	+200,000	New	+$4.09M	0.28%	63

Perceptive Advisors's PPHMP Position: Q2 2017 in Review

Perceptive Advisors sold out of Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) in Q2 2017, closing a stake of 200,000 shares — an estimated $4.34M sold.

Perceptive Advisors first reported a position in PPHMP in Q4 2016 and held it in 2 quarters. The position peaked at $4.34M in Q1 2017. 0 funds tracked by Wall St. Rank hold PPHMP as of Q2 2017.

Perceptive Advisors reported no remaining Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible position as of Q2 2017 after selling out during the quarter.
Perceptive Advisors sold 200,000 Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible shares in Q2 2017, an estimated $4.34M.
Perceptive Advisors first reported a position in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible in Q4 2016 and held it in 2 quarters.
Perceptive Advisors's Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible position peaked at $4.34M in Q1 2017.
0 funds tracked by Wall St. Rank held Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.